Paul Turner

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

Kevin M. Foote, J. Willem M. Nissink, Thomas M. McGuire et al. · Journal of Medicinal Chemistry · 2018 · 313 citations · Full text

Kinase Ataxia Telangiectasia, Cell Death, Molecular Biology +19

Gold and BINOL-Phosphoric Acid Catalyzed Enantioselective Hydroamination/<i>N</i>-Sulfonyliminium Cyclization Cascade

Alex W. Gregory, Pavol Jakubec, Paul Turner et al. · Organic Letters · 2013 · 98 citations · Full text

Chemical Engineering, Subsequent Phosphoric Acid, Sulfonamide Scaffolds +9

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy

Catherine E. Willoughby, Yanyan Jiang, Huw D. Thomas et al. · Journal of Clinical Investigation · 2019 · 64 citations · Full text

Radiation Therapy, Therapeutic Index, Medicine +15

Abstract 2348: Discovery of AZD6738, a potent and selective inhibitor with the potential to test the clinical efficacy of ATR kinase inhibition in cancer patients.

Clifford D. Jones, Kevin Blades, Kevin M. Foote et al. · Cancer Research · 2013 · 37 citations

Molecular Biology, Cancer Patients, Molecular Pharmacology +22

Modified Carbobenzyloxy Groups in Peptide Synthesis

D. M. Channing, Paul Turner, G. T. Young · Nature · 1951 · 26 citations

Peptide Engineering, Peptide Synthesis, Biomolecular Engineering +1